Previous 10 | Next 10 |
Recent news releases related news releases and press releases from 11/07/23 07:09:14 on US and Canada Markets.
Revenues G rew 6% to $63.9 million ; GAAP Operating Income of $12.7 million and A djusted EBITDA of $9.5 million, 30% Growth Y ear-over- Y ear ; PETAH TIKVA, Israel, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Gilat Sat...
CHICAGO, IL - ( NewMediaWire ) - November 07, 2023 - Epazz, Inc. (OTC: EPAZ), A mission-critical provider of drone technology, artificial intelligence software, cryptocurrency apps, blockchain mobile apps, and cloud-based business software solutions, has exciting news to share today. Epazz,...
~ Announced FDA clearance of Investigational New Drug (IND) application for AMT-260 in refractory mesial temporal lobe epilepsy ~ ~ On track to provide clinical update from U.S. and European Phase I/II trials of AMT-130 in Huntington’s disease later in the fourth quarter ...
Cloud-based Universal ZTNA to offer network access control, access point and switch security within a single solution, creating a frictionless user experience and consistent security policy Extreme Networks™, Inc. (Nasdaq: EXTR), a leader in cloud networking, today introduced...
VANCOUVER, BC / ACCESSWIRE / November 7, 2023 / Aton Resources Inc. (TSXV:AAN) ("Aton" or the "Company") is pleased to update investors on the latest results from the recent reverse circulation percussion ("RC") drilling at the Semna prospect, located within its 100% owned Abu Marawat Concession...
Financial Overview - Third Quarter Revenues of $139 Million, Down 4% From a Year Ago Adjusted Operating Income Margin of 8.5%, GAAP Operating Loss Margin of (19.2)% Adjusted EPS of $0.12; GAAP Diluted EPS of $(0.27) Financial Overview - Nine Months Revenues of $4...
LONDON and SALT LAKE CITY, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that it will report its first quarter fiscal year 2024 financial results on Tuesday, November 14, 2023, before market open. The Company will host a corresponding conference call and liv...
Advancing dose escalation portion of Phase 1 clinical trial of XMT-1660, Mersana’s B7-H4 Dolasynthen ADC Preparations underway to resume enrollment in Phase 1 clinical trial of XMT-2056, Mersana’s HER2 Immunosynthen ADC Capital resources expected to support current o...
– Enrollment continues in the 2L Phase 3 VERITAC-2 trial and study lead-in for the VERITAC-3 1L Phase 3 trial with vepdegestrant; Top-line data readout for VERITAC-2 remains on-track for 2H 2024 – – Bavdegalutamide mCRPC data presented at ESMO showed median rPFS of ...
TORONTO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Latitude Uranium Inc. (“Latitude Uranium”, “LUR” or the “Company”) (CSE: LUR, OTCQB: LURAF, FRA: EI1) is pleased to announce the first batch of assay results from its 2023 drill program at the Angilak Project...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
19.02%Change Percent:
Cognition Therapeutics Inc. Company Name:
CGTX Stock Symbol:
NASDAQ Market:
cogrx.com Website: